Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGOPSYCH agomelatine for depressive episodes in schizophrenia-spectrum psychosis
2012-004079-38Phase 4Active
- Sponsor
- Central Institute of Mental Health
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive episode (MDE) and Schizophrenia Spectrum Disorders (SSD), sponsored by Central Institute of Mental Health. Primary endpoints: Primary efficacy endpoint, HAM-D17 change from baseline to week 6 and 1 more. Started Dec 2012; status: active.
02
Drugs
agomelatine
03
Conditions
major depressive episode (MDE)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2012-004079-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004079-38.